Abstract

PRESCRIPTION PATTERN AND COST ANALYSIS OF PROTON PUMP INHIBITORS IN SECONDARY HEALTHCARE HOSPITAL IN DHARMAPURI

Tamilselvan G.*, Senthil Kumar K. L., Suresh V., Praveen G., Praveen K. and Praveen Kumar G.

ABSTRACT

The goal of our study was to estimate the cost of the IV and oral proton pump inhibitor and Controlling medicine cost. To assess the rationality of prescribing oral and IV proton pump inhibitors in secondary health care hospital in Dharmapuri, Tamil Nadu, India. In this retrospective study conducted in the duration of study is 6 months from June 2022 to November 2022. Out of 100 patients with Peptic ulcer disease were collected in this present study. 63% male was a high frequency of peptic ulcer disease incidence as a compared to 37% of female patients. Most of the patients diagnosed with Peptic ulcer were of the age group of 41-60 (49%). In the observation study Pan was administered in 63% patients followed by Rablet in 12% patients, Esomac in 17% patients, Omez in 5% patients and Rabicip in 3% patient. Indication for giving PPI in 39% Patients were received PPIs for Comorbidities these are the majority. The route of administration study included, the majority of 63% patients were received PPI through intravenous route and 37% patients received through Oral route. The cost of pan 40 was reasonable compared to the other prescribed brands. Among all the prescribed PPIs, pantoprazole average therapy cost is highest still prescribed to the highest number of patients.

Keywords: cost, proton pump inhibitors, oral, brands.